MAY 14·Stock TitanMed
CytoSorbents (CTSO) posts wider Q1 2026 loss and flags going-concern risk
CytoSorbents (CTSO) reported a wider net loss of $5.1 million in Q1 2026, an increase from $1.5 million in Q1 2025, despite a slight revenue increase to $8.9 million. The company's cash position of $6.3 million against $18.4 million in debt has raised "substantial doubt" about its ability to continue as a going concern for the next 12 months. CytoSorbents is implementing a cost reduction plan and seeking additional financing while pursuing FDA approval for its DrugSorb-ATR device.